Ruxolitinib (Opzelura) cream can help repigment the skin in many body areas affected with vitiligo, researchers reported at the European Academy of Dermatology and Venereology (EADV) 2022 Annual ...

Once-daily ritlecitinib demonstrated clinically meaningful improvements in nonsegmental vitiligo on the face and body in ...

Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin repigmentation in people with vitiligo, paving the way for additional oral and topical JAK inhibitors to treat this autoimmune ...

Ash Soto is known on social media as "the girl with the world painted on her body" Ash Soto wants others to learn to love themselves. Known on social media as “the girl with the world painted on her ...

Vitiligo typically begins on the hands, forearm, feet and face. But, it can develop on any part of the body, including the mucous membranes (moist lining of the mouth, nose, genitals and rectal area), ...

Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a ...

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older ...

This article is sponsored by Incyte. Vitiligo is a chronic autoimmune condition that manifests as white patches of depigmented skin, or a complete loss of color, on affected areas of the body. The ...

- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...

Vitiligo is an autoimmune disease known for causing a loss of pigment-making skin cells called melanocytes, leading to patches of color loss. It may develop at any age, usually starting before you are ...